Andrew Huberman· PhD
but only in two cancers melanoma and kidney cancer and only at very small levels about 10% of the population would respond to these things
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
but only in two cancers melanoma and kidney cancer and only at very small levels about 10% of the population would respond to these things
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and by the way that could be going back to gen 1 immunotherapy which is interleukin-2 interleukin-2 had about a maybe a 10 to 20 response rate in melanoma a particularly immune sensitive cancer but but that was treating patients with full-blown metastatic melanoma maybe it would look very different in patients who were nad or who are you know visibly without disease